Get the Stockscreener App
1.9116
0.61%
0.0116
Vyne Therapeutics Inc stock is traded at $1.9116, with a volume of 1,971.
It is up +0.61% in the last 24 hours and down -22.61% over the past month.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
See More
Previous Close:
$1.90
Open:
$1.87
24h Volume:
1,971
Relative Volume:
0.02
Market Cap:
$28.44M
Revenue:
$486.00K
Net Income/Loss:
$-28.43M
P/E Ratio:
-0.6781
EPS:
-2.8189
Net Cash Flow:
$-26.75M
1W Performance:
-12.71%
1M Performance:
-22.61%
6M Performance:
+3.89%
1Y Performance:
-7.20%
1-Day Range:
$1.87
$1.93
1-Week Range:
$1.7701
$2.24
52-Week Range:
$1.57
$4.30
Vyne Therapeutics Inc Stock (VYNE) Company Profile
Name
Vyne Therapeutics Inc
Sector
Industry
Phone
800-775-7936
Address
685 ROUTE 202/206 N., SUITE 301, BRIDGEWATER
Compare VYNE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VYNE
Vyne Therapeutics Inc
|
1.92 | 28.44M | 486.00K | -28.43M | -26.75M | -2.8189 |
|
VRTX
Vertex Pharmaceuticals Inc
|
508.46 | 130.68B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
679.83 | 74.97B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.43 | 36.08B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.91 | 31.19B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.51 | 27.56B | 3.32B | -860.46M | -1.04B | -8.32 |
Vyne Therapeutics Inc Stock (VYNE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-24 | Initiated | BTIG Research | Buy |
| Dec-06-21 | Resumed | H.C. Wainwright | Buy |
Vyne Therapeutics Inc Stock (VYNE) Latest News
VYNE Therapeutics (NASDAQ:VYNE) Earns “Buy” Rating from HC Wainwright - Defense World
VYNE Therapeutics Reports Progress in Clinical Trials - TipRanks
VYNE Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
VYNE Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Est - GuruFocus.com
VYNE Therapeutics Inc. (VYNE) reports earnings - Quartz
VYNE Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) - Benzinga
Vyne Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update - The Manila Times
Can VYNE's $61.5M War Chest Drive Success in Vitiligo and Psoriasis Trials? - StockTitan
VYNE Therapeutics reports Q4 EPS (28c) vs (20c) last year - TipRanks
VYNE Therapeutics (VYNE) Projected to Post Quarterly Earnings on Thursday - Defense World
HC Wainwright Reiterates “Buy” Rating for VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics to Participate in March Investor Conferences - The Manila Times
Can VYNE Therapeutics' March Investor Conferences Reveal New Strategic Directions? - StockTitan
VYNE Therapeutics Inc. Initiates Phase 1B Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - Marketscreener.com
VYNE Therapeutics Initiates Phase 1b Trial Of VYN202 For Plaque Psoriasis Treatment - Nasdaq
Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis - Marketscreener.com
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis - The Manila Times
Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details - StockTitan
Vyne therapeutics director Patrick Lepore buys $43,800 in stock - MSN
VYNE Therapeutics Updates Corporate Presentation and Pipeline Progress - Defense World
Vyne therapeutics director Patrick Lepore buys $43,800 in stock By Investing.com - Investing.com Australia
Insider Buying: Patrick Lepore Acquires 15,000 Shares of VYNE Th - GuruFocus.com
VYNE Therapeutics (NASDAQ:VYNE) Given Buy Rating at HC Wainwright - MarketBeat
Acne Vulgaris Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, MOA, ROA by DelveInsight | Dermata Therapeutics, AstraZeneca, Novartis, UCB Pharma, Incyte Inc., Galderma - The Globe and Mail
Financial Analysis: Skye Bioscience (NASDAQ:SKYE) vs. VYNE Therapeutics (NASDAQ:VYNE) - Defense World
VYNE Therapeutics completes enrolment in trial of gel for non-segmental vitiligo - Yahoo Finance
VYNE Therapeutics’ (VYNE) Buy Rating Reaffirmed at HC Wainwright - Defense World
Forecasting The Future: 4 Analyst Projections For VYNE Therapeutics - Benzinga
VYNE Therapeutics' (VYNE) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
VYNE Therapeutics Completes Enrollment in Phase 2B Trial Evaluating Vyn201 for the Treatment of Nonsegmental Vitiligo - Marketscreener.com
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluat - WICZ
VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201 - StockTitan
VYNE stock soars to 52-week high, touches $3.43 By Investing.com - Investing.com South Africa
VYNE stock soars to 52-week high, touches $3.43 - Investing.com
VYNE Therapeutics Reports Positive Phase 1a MAD Data for VYN202 - Defense World
H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data - Yahoo Finance
VYNE Therapeutics’ (VYNE) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
VYNE Therapeutics Reports Positive Phase 1a MAD Data for BD2-Selective BET Inhibitor VYN202 - Dermatology Times
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor - The Manila Times
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Drops By 37.1% - Defense World
VYNE Therapeutics Sees Strong Shareholder Support for Growth - TipRanks
Prurigo Nodularis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therap - The Globe and Mail
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates - MSN
VYNE Therapeutics initiated with a Buy at BTIG on I&I potential - Yahoo Finance
BTIG Initiates Coverage of VYNE Therapeutics (VYNE) with Buy Recommendation - MSN
VYNE Therapeutics’ (VYNE) Buy Rating Reiterated at HC Wainwright - Defense World
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
VYNE Therapeutics Advances Clinical Pipeline in Q3 2024 - TipRanks
Vyne Therapeutics Inc Stock (VYNE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.28%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):